

Daily Research Report

Dt.: 29 Oct, 2026

INDEX	NIFTY	BANKNIFTY	USDINR
Outlook	Neutral	Neutral	Neutral

INSTITUTIONAL TRADING ACTIVITY IN CRS.

Category	Buy Value	Sell Value	Net Value
FII	16834.53	15962.70	+871.83
DII	17240.09	16997.55	+643.35

TRADE STATISTICS FOR 28/10/2026

Instrument	No. of Contracts	Turnover (Cr.)	Put Call Ratio
Index Fut.	109022	16493.67	
Stock Fut.	1061938	64602.33	
Index Opt.	62253311	9242616	1.15
Stock Opt.	6086030	385049.1	
F&O Total	69510301	9708761	

Nifty Action: 28/10/2026



PIVOT TABLE					
	R2	R1	PIVOT	S1	S2
NIFTY	22903	22846	22738	22647	22454
BANKNIFTY	55138	54435	54193	53732	53029

NIFTY FUT.			
	TRIGGER	T1	T2
Above	23000	23210	23295
Below	22400	21922	21827

BANK NIFTY FUT.			
	TRIGGER	T1	T2
Above	56000	56450	57072
Below	54200	53524	52578

NIFTY CHART



Nifty remains in a fragile stabilisation phase. Yesterday's recovery from the 22500 area indicates buying interest at lower levels; however, the index has yet to reclaim its 20 DEMA resistance. A sustained move above 22865 is essential to strengthen the rebound and open the way towards 23000–23100. Momentum indicators remain weak, with RSI holding below 50, while ADX has moved above 25, signalling strengthening trend intensity and raising the risk that the prevailing downtrend could persist. A meaningful reversal therefore requires follow-through buying and improving market breadth. On the downside, failure to hold 22,500 would weaken the stabilisation attempt and bring 22370 into focus. A decisive closing break below 22370 could accelerate selling towards 22060. The broader November expiry range of 22060–23350 remains relevant, with a decisive breakout beyond either boundary potentially signalling a stronger directional move. Trading stance: Avoid chasing intraday breakouts and seek a convincing close with follow-through before increasing directional exposure. Until key resistance is reclaimed, maintain a defensive stance and prioritise capital protection.

Trade Scanner: AUOPHARMA, BANKINDIA, BSE, FEDERALBNK, GMRAIRPORT, GODREJPROP, HDFCAMC, HINDALCO, INDUSINDBK, LODHA, LUPIN, MAXHEALTH, POWERINDIA, TRENT. DLF, FORCEMOT, HINDUNILVR, ICICIGI, INDIANB, MFSL, PIDILITIND, SBICARD, TATASTEEL, TCS,

RESEARCH DESK: Sacchitanand Uttakar - VP - Research (Derivatives & Technicals)

Disclaimer: Investments in securities market are subject to market risk, read all the related documents carefully before investing.

The securities quoted are for illustration only and are not recommendatory | Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Disclaimer: This document is for private circulation and information purpose only and should not be regarded as an investment, trading, taxation, legal or price? risk management advice. In no circumstances it is considered as an offer to sale or a solicitation of any offer to buy or sell the Equity derivatives mentioned herein. We and our affiliates, group? companies, directors and employees, and directors and employees of our affiliates and group? companies, including persons involved in the preparation or issuance of this material may (a) have positions in Equity (derivatives or physical) mentioned hereby or (b) have other positions which might have conflicting interest with respect to any related information. The information contained hereby may have been taken from sources which we believe are reliable. We do not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinion expressed reflects judgments at this date and are subject to change without notice. Risk of loss in Equity derivatives trading can be substantial. Persons trading in Equity Derivatives should consider the suitability of trading based upon their resources, risk appetite and other relevant information; and understand that statements regarding future prospects may not be realized.